964.04
price up icon3.31%   29.44
after-market After Hours: 962.00 -2.04 -0.21%
loading
Lilly Eli Co stock is traded at $964.04, with a volume of 3.65M. It is up +3.31% in the last 24 hours and up +1.16% over the past month. Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
See More
Previous Close:
$934.60
Open:
$955.18
24h Volume:
3.65M
Relative Volume:
1.13
Market Cap:
$860.94B
Revenue:
$72.25B
Net Income/Loss:
$25.28B
P/E Ratio:
34.70
EPS:
27.7808
Net Cash Flow:
$5.96B
1W Performance:
+9.23%
1M Performance:
+1.16%
6M Performance:
+11.90%
1Y Performance:
+21.59%
1-Day Range:
Value
$950.97
$984.45
1-Week Range:
Value
$850.51
$984.45
52-Week Range:
Value
$623.78
$1,133.95

Lilly Eli Co Stock (LLY) Company Profile

Name
Name
Lilly Eli Co
Name
Phone
(317) 276-2000
Name
Address
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Name
Employee
50,000
Name
Twitter
@LillyPad
Name
Next Earnings Date
2026-04-30
Name
Latest SEC Filings
Name
LLY's Discussions on Twitter

Compare LLY vs JNJ, ABBV, AZN, NVS

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
LLY icon
LLY
Lilly Eli Co
963.71 780.79B 72.25B 25.28B 5.96B 27.78
JNJ icon
JNJ
Johnson Johnson
227.20 548.34B 96.36B 21.04B 17.80B 8.6488
ABBV icon
ABBV
Abbvie Inc
206.61 349.67B 62.82B 3.62B 17.82B 2.0331
AZN icon
AZN
Astrazeneca Plc
184.82 289.51B 60.48B 10.40B 8.05B 3.3297
NVS icon
NVS
Novartis Ag Adr
146.59 277.63B 54.66B 13.58B 16.05B 7.0171

Lilly Eli Co Stock (LLY) Upgrades & Downgrades

Date Action Analyst Rating Change
Mar-17-26 Downgrade HSBC Securities Hold → Reduce
Feb-25-26 Initiated RBC Capital Mkts Outperform
Feb-20-26 Initiated Barclays Overweight
Jan-07-26 Resumed UBS Buy
Dec-16-25 Upgrade Daiwa Securities Neutral → Buy
Dec-15-25 Reiterated BofA Securities Buy
Dec-15-25 Reiterated Goldman Buy
Nov-13-25 Initiated Scotiabank Sector Outperform
Nov-10-25 Upgrade Leerink Partners Market Perform → Outperform
Oct-20-25 Reiterated BMO Capital Markets Outperform
Oct-14-25 Upgrade Erste Group Hold → Buy
Sep-17-25 Downgrade Berenberg Buy → Hold
Aug-27-25 Upgrade HSBC Securities Reduce → Hold
Aug-18-25 Downgrade Daiwa Securities Outperform → Neutral
Aug-07-25 Downgrade Leerink Partners Outperform → Market Perform
Jun-05-25 Downgrade Erste Group Buy → Hold
Apr-28-25 Downgrade HSBC Securities Buy → Reduce
Apr-22-25 Initiated Cantor Fitzgerald Overweight
Dec-10-24 Resumed BofA Securities Buy
Nov-15-24 Initiated Wolfe Research Outperform
Oct-17-24 Initiated Bernstein Outperform
Sep-13-24 Resumed Citigroup Buy
Aug-12-24 Upgrade Deutsche Bank Hold → Buy
Feb-21-24 Downgrade DZ Bank Buy → Hold
Feb-16-24 Reiterated Morgan Stanley Overweight
Dec-21-23 Downgrade Daiwa Securities Buy → Outperform
Nov-09-23 Initiated Deutsche Bank Hold
Oct-20-23 Resumed UBS Buy
Aug-09-23 Upgrade Jefferies Hold → Buy
Jul-26-23 Reiterated Citigroup Buy
Jul-14-23 Initiated HSBC Securities Buy
May-24-23 Reiterated BofA Securities Buy
May-24-23 Reiterated UBS Buy
Mar-13-23 Upgrade Wells Fargo Equal Weight → Overweight
Mar-06-23 Initiated Jefferies Hold
Feb-15-23 Downgrade Societe Generale Hold → Sell
Nov-18-22 Initiated Credit Suisse Outperform
Sep-22-22 Upgrade UBS Neutral → Buy
May-23-22 Initiated SVB Leerink Outperform
Apr-06-22 Resumed Morgan Stanley Overweight
Mar-10-22 Initiated Daiwa Securities Outperform
Jan-21-22 Upgrade DZ Bank Hold → Buy
Jan-03-22 Reiterated Bernstein Mkt Perform
Dec-17-21 Initiated Goldman Neutral
Dec-16-21 Reiterated BMO Capital Markets Outperform
Dec-16-21 Reiterated BofA Securities Buy
Dec-09-21 Resumed Wells Fargo Equal Weight
Nov-19-21 Initiated BMO Capital Markets Outperform
Oct-11-21 Upgrade Berenberg Hold → Buy
Sep-29-21 Upgrade Citigroup Neutral → Buy
Aug-05-21 Upgrade DZ Bank Hold → Buy
Jul-27-21 Resumed Truist Buy
Jun-24-21 Reiterated Cantor Fitzgerald Overweight
Jan-19-21 Upgrade Mizuho Neutral → Buy
Dec-10-20 Upgrade Wolfe Research Peer Perform → Outperform
Nov-10-20 Resumed Bernstein Mkt Perform
Sep-29-20 Initiated Berenberg Hold
Sep-03-20 Upgrade Morgan Stanley Equal-Weight → Overweight
Jun-16-20 Upgrade Guggenheim Neutral → Buy
Apr-21-20 Downgrade UBS Buy → Neutral
Apr-09-20 Downgrade Morgan Stanley Overweight → Equal-Weight
Feb-06-20 Initiated Mizuho Neutral
Dec-18-19 Upgrade Morgan Stanley Equal-Weight → Overweight
Oct-17-19 Resumed BofA/Merrill Buy
May-28-19 Initiated Goldman Buy
Apr-24-19 Upgrade Edward Jones Hold → Buy
Apr-11-19 Downgrade Guggenheim Buy → Neutral
Mar-12-19 Initiated JP Morgan Overweight
Jan-23-19 Initiated UBS Buy
Nov-26-18 Downgrade Citigroup Buy → Neutral
Oct-31-18 Upgrade Credit Suisse Underperform → Neutral
Oct-09-18 Initiated Guggenheim Buy
Oct-01-18 Reiterated SunTrust Buy
Sep-26-18 Resumed JP Morgan Overweight
View All

Lilly Eli Co Stock (LLY) Latest News

pulisher
03:18 AM

LLY Maintains Overweight by Cantor Fitzgerald -- Price Target Ra - GuruFocus

03:18 AM
pulisher
02:45 AM

Lilly’s Double-Beat Widens the GLP-1 Gap—And a New Pill Could Make It Permanent - Investing.com

02:45 AM
pulisher
01:05 AM

Lilly's Double-Beat Widens the GLP-1 Gap—And a New Pill Could Make It Permanent - MarketBeat

01:05 AM
pulisher
11:58 AM

BofA cuts Eli Lilly stock price target on valuation concerns - Investing.com

11:58 AM
pulisher
10:42 AM

Raised guidance lifts Eli Lilly stock to fresh highs in strong session - Traders Union

10:42 AM
pulisher
10:41 AM

Why is Eli Lilly stock surging today? - Investing.com

10:41 AM
pulisher
10:16 AM

Eli Lilly and Co Stock (LLY) Moved Up by 4.44% on May 1: Facts Behind the Movement - TradingKey

10:16 AM
pulisher
09:53 AM

Cantor Fitzgerald Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Raises Target Price to $1,230 - 富途牛牛

09:53 AM
pulisher
09:27 AM

Eli Lilly Jumps As Earnings Beat Meets FDA Tightening Drug Compounding Rules - Benzinga

09:27 AM
pulisher
08:37 AM

Eli Lilly and Company (NYSE:LLY) Q1 2026 Earnings Call Transcript - Insider Monkey

08:37 AM
pulisher
08:19 AM

Cantor Fitzgerald raises Eli Lilly stock price target on guidance By Investing.com - Investing.com Canada

08:19 AM
pulisher
07:58 AM

Lilly's obesity pill hits nearly 6,000 prescriptions in third week after launch - Reuters

07:58 AM
pulisher
07:57 AM

Lilly Boosts Sales View to $85 Billion on Obesity-Drug Surge - Advisor Perspectives

07:57 AM
pulisher
07:30 AM

Eli Lilly: The Most Expensive Stock in Pharma; and Maybe the Best - TradingView

07:30 AM
pulisher
07:17 AM

Lilly’s new weight loss pill sees rising demand - Latest news from Azerbaijan

07:17 AM
pulisher
06:39 AM

Goldman Sachs Adjusts PT on Eli Lilly and Co. to $1,283 From $1,260, Maintains Buy Rating - Moomoo

06:39 AM
pulisher
06:37 AM

Leerink Partners Adjusts PT on Eli Lilly and Co. to $1,119 From $1,058, Maintains Outperform Rating - marketscreener.com

06:37 AM
pulisher
04:04 AM

Why Eli Lilly and Company (LLY) is One of the Best Drug Stocks to Buy According to Analysts - Insider Monkey

04:04 AM
pulisher
02:53 AM

Eli Lilly (LLY) Net Margin At 31.7% Tests Justification For 40.5x P/E Narrative - simplywall.st

02:53 AM
pulisher
02:20 AM

Eli Lilly Capitalizes On Consumers' 'Love Affair' With Weight Loss Drugs: Gary Black Says Valuation 'Stil - Benzinga

02:20 AM
pulisher
01:58 AM

Truist Securities: Eli Lilly's Incretin Portfolio Bolsters Multi-year Growth Potential; Estimates Updated - 富途牛牛

01:58 AM
pulisher
01:39 AM

BMO Adjusts Model for Eli Lilly After 'Standout' Q1 - Moomoo

01:39 AM
pulisher
01:33 AM

RBC Ups Estimates for Eli Lilly Post-Q1 Results; Outperform Rating Kept - 富途牛牛

01:33 AM
pulisher
12:21 PM

With Earnings Booming, Can Lilly Hold Its Pharma Crown? - Moomoo

12:21 PM
pulisher
12:04 PM

Eli Lilly Sales Surge 56% as Booming GLP-1 Demand Eclipses Lower Prices - The Daily Upside

12:04 PM
pulisher
Apr 30, 2026

US FDA proposes curbs on mass compounding of Novo, Lilly's weight-loss drugs - Reuters

Apr 30, 2026
pulisher
Apr 30, 2026

Eli Lilly Q1 Revenue Hits $19.8B as GLP-1 Drugs Fuel Growth - Fitt Insider

Apr 30, 2026
pulisher
Apr 30, 2026

GLP-1 Sales Continue to Lift Eli Lilly. Does That Make LLY Stock a Buy? - Barchart

Apr 30, 2026
pulisher
Apr 30, 2026

Eli Lilly Earnings: Mounjaro/Zepbound's Massive Volume Growth More Than Counters Price Pressure - Morningstar

Apr 30, 2026
pulisher
Apr 30, 2026

Eli Lilly and Co Options Spot-On: On April 30th, 89,364 Contracts Were Traded, With 341.58K Open Interest - Moomoo

Apr 30, 2026
pulisher
Apr 30, 2026

Eli Lilly Stock Jumps on Earnings Beat as Zepbound and Mounjaro Sales Skyrocket -- Barrons.com - 富途牛牛

Apr 30, 2026
pulisher
Apr 30, 2026

Eli Lilly's Cardiometabolic Dominance Is Driving Stellar Growth and Supports a Wide Moat - Morningstar

Apr 30, 2026
pulisher
Apr 30, 2026

Lilly’s Strong GLP-1 Results Signal Robust Market Growth for Novo Nordisk says Barclays - Investing.com

Apr 30, 2026
pulisher
Apr 30, 2026

Eli Lilly (LLY) Q1 2026 Earnings Call Transcript - Fortune

Apr 30, 2026
pulisher
Apr 30, 2026

Friday Five — Pfizer's LOE reprieve, Lilly's outsized earnings, Chiesi snaps up KalVista, and more… - FirstWord Pharma

Apr 30, 2026
pulisher
Apr 30, 2026

More than 20k people on oral weight loss pill as Lilly ramps up access - IndyStar

Apr 30, 2026
pulisher
Apr 30, 2026

Market movers: Qualcomm, Hertz, Eli Lilly, Royal Caribbean, 374Water… - Proactive financial news

Apr 30, 2026
pulisher
Apr 30, 2026

Eli Lilly’s proven $19.8B quarter and what’s next - Rolling Out

Apr 30, 2026
pulisher
Apr 30, 2026

Eli Lilly quells fears that its GLP-1 pill debut is off to a rocky start - Sherwood News

Apr 30, 2026
pulisher
Apr 30, 2026

Why Eli Lilly stock just popped - MSN

Apr 30, 2026
pulisher
Apr 30, 2026

High-flying Lilly delivers Q1 show of strength - The Pharma Letter

Apr 30, 2026
pulisher
Apr 30, 2026

Eli Lilly (LLY) Q1 2026 Earnings Transcript - The Motley Fool

Apr 30, 2026
pulisher
Apr 30, 2026

Lilly lifts profit forecast as surging demand for weight-loss drugs offsets pricing pressure - Reuters

Apr 30, 2026
pulisher
Apr 30, 2026

Lilly earnings increase as Mounjaro, Zepbound sales continue rise - Inside INdiana Business

Apr 30, 2026
pulisher
Apr 30, 2026

Lilly touts 'encouraging' early days for Foundayo obesity launch, even as GLP-1 pill appears to lag Novo's - Fierce Pharma

Apr 30, 2026
pulisher
Apr 30, 2026

Why Eli Lilly Stock Just Popped - AOL.com

Apr 30, 2026
pulisher
Apr 30, 2026

Confo Therapeutics Announces Phase 2 Clinical Trial Initiation by Lilly for Peripheral Pain Candidate, CFTX-1554 - Yahoo Finance

Apr 30, 2026
pulisher
Apr 30, 2026

Eli Lilly Q1 2026 Earnings Call Transcript - Benzinga

Apr 30, 2026
pulisher
Apr 30, 2026

Incretin boom lifts Eli Lilly (NYSE: LLY) Q1 profit 168% - Stock Titan

Apr 30, 2026
pulisher
Apr 30, 2026

Why is Eli Lilly stock surging today? By Investing.com - Investing.com India

Apr 30, 2026
pulisher
Apr 30, 2026

Lilly surges on earnings beat and raised guidance - Investing.com

Apr 30, 2026

Lilly Eli Co Stock (LLY) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Lilly Eli Co Stock (LLY) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Montarce Lucas
EVP & CFO
Feb 16 '26
Option Exercise
0.00
368
0
16,418
Custer Kenneth L.
EVP & President, Card Met Hlth
Feb 16 '26
Option Exercise
0.00
207
0
10,232
Brown Adrienne S
EVP, President LLY Imm
Feb 16 '26
Option Exercise
0.00
391
0
5,312
Yuffa Ilya
EVP&Pres, LLY USA&Global Capab
Feb 01 '26
Option Exercise
0.00
3,394
0
29,654
Skovronsky Daniel
EVP, CS&PO & Pres. LRL
Feb 01 '26
Option Exercise
0.00
12,684
0
150,165
Van Naarden Jacob
EVP,Pres LLY Oncology&HdCorpBD
Feb 01 '26
Option Exercise
0.00
4,108
0
24,670
Ricks David A
President, Chair, and CEO
Feb 01 '26
Option Exercise
0.00
31,932
0
547,098
Rau Diogo
EVP & CIDO
Feb 01 '26
Option Exercise
0.00
3,752
0
23,471
Jonsson Patrik
EVP & President, LLY Int'l
Feb 01 '26
Option Exercise
0.00
3,930
0
57,581
Hernandez Edgardo
EVP & Pres., Mfg. Operations
Feb 01 '26
Option Exercise
0.00
3,572
0
43,303
JNJ JNJ
$227.20
price down icon 1.03%
$206.61
price down icon 2.22%
AZN AZN
$184.82
price down icon 1.54%
NVS NVS
$146.59
price down icon 0.81%
MRK MRK
$112.17
price up icon 2.87%
Cap:     |  Volume (24h):